- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
GLP-1RAs for Weight Management: Weighing Benefits vs Side Effects
Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.
"When considering glucagon-like peptide-1 (GLP-1) receptor agonists for weight management in patients with obesity, how do you weigh the benefits against potential side effects, especially in patients with comorbidities?”
That is a question Patient Care Online asked obesity medicine specialist Michael Crotty, MD, in a recent interview. In the video above, Dr Crotty discusses the benefits of GLP-1 receptor agonists in weight management and their impact on health. He also emphasizes the importance of treating obesity as a chronic disease with evidence-based treatments, from foundational lifestyle interventions and behavioral support to pharmacotherapy and surgery.
RELATED: Expanding the Obesity Treatment Toolbox: The Promise of Dual-Action Medications
Dr Crotty is also the co-founder and clinical lead of My Best Weight in Dublin, Ireland.
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
